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In human obesity, white adipose tissue (WAT) is enriched 
in macrophages. How macrophage infiltration in WAT con- 
tributes to the complications of obesity is unknown. This 
study tested the hypothesis that recruitment of macrophages 
in omental WAT is associated with hepatic damage in obese 
patients. Paired biopsies of subcutaneous and omental WAT 
and a liver biopsy were collected during gastric surgery in 
46 obese women and 9 obese men (BMI 47.9 ± 0.93 kg/m2). 
The number of HAM56+ macrophages in WAT was quanti- 
fied microscopically, and correlations with clinical and 
biological parameters and histological liver pathology were 
investigated. There were twice as many macrophages in 
omental as in subcutaneous WAT (P < 0.0001). After 
adjustment for age, omental WAT macrophage infiltration 
was correlated to fasting glucose and insulin, quantitative 
insulin sensitivity check index, triglycerides, aspartate 
aminotransferase (AST), and )'-glutamyltranspeptidase. 
We propose an easy equation to estimate the amount of 
macrophages in omental WAT. Increased macrophage accu- 
mulation specifically in omental WAT was associated with 
hepatic fibroinflammatory lesions (P 0.01). The best 
predictive model for the severity of hepatic damage in- 
cludes adiponectinemia, AST, and omental WAT macro- 
phages. These data suggest that the presence of 
macrophages in omental WAT participates in the cellular 
mechanisms favoring hepatic fibroinflammatory lesions in 
obese patients.  
 
acrophages are mononuclear phagocytes in- 
volved in immunological and inflammatory 
processes, whose specific function is to pro- 
vide an immediate defense against foreign 
elements such as pathogens and dead cells. Resident 
macrophages are found in virtually all tissues (1). How- 
ever, the presence of macrophages in white adipose tissue 
(WAT) has gone almost unnoticed, except for specific 
experimental conditions leading to adipose cell death in 
mice (2). It is now established that macrophages are 
scarce in the WAT of normal-weight individuals, but they 
increase markedly in animal models and in human obesity 
(3– 6). Transplantation studies in mice suggest that these 
macrophages derive mostly from the bone marrow (3) 
rather than from preadipocyte differentiation toward mac- 
rophage lineage (7,8). 
The causes and consequences of macrophage recruit- 
ment in WAT are poorly understood. Substantial infiltra- 
tion of inflammatory cells around necrotic-like adipocytes 
has been reported in experimental models of adipose cell 
death (2,9). In humans, the presence of CD68-positive 
macrophages in direct contact with mature adipocytes has 
been noted on adipose tissue slides (10). More recently, 
arrangement of macrophages in a “crown” around single 
adipocytes exhibiting features of necrosis has been re- 
   ported in obese subjects (6,11). These observations sug- 
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showing that a weight loss–induced improvement of sys- 
temic inflammation is associated with a reduction in 
macrophage infiltration and improvement of the inflamma- 
tory profile in subcutaneous WAT (6,12). It has been 
suggested that WAT macrophages may play a role in the 
etiopathogenesis of obesity comorbidities. This is sup- 
ported by results showing that macrophage accumulation 
in WAT precedes high-fat diet–induced hyperinsulinemia 
in mice, suggesting a causative link between WAT macro- 
phages and insulin resistance (4). Similarly, deletion of 
CCR2 (chemokine receptor-2) lowered the macrophage 
content of epididymal WAT and improved systemic glu- 
cose homeostasis and insulin sensitivity in obese mice 
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TABLE 1 
Clinical and biological parameters of 55 morbidly obese subjects 
 
Phenotype Whole population Liver subset 
n 55 39 
F/M 46/9 (83) 31/8 (80) 
Age (years) 
BMI (kg/m2) 
39.5 ± 1.44 
47.9 ± 0.93 
38.3 ± 1.63 
47.8 ± 1.15 
Glucose homeostasis   
Glucose (mmol/l) 6.15 ± 0.29 6.24 ± 0.33 
Insulin (µU/ml) 15.0 ± 1.27 15.6 ± 1.44 
QUICKI 0.32 0.32 
Type 2 diabetes 
Glycemia >7 mmol/l or treatment 12/55 (22) 9/39 (23) 
Lipids homeostasis 
 
Cholesterol  (mmol/l) 5.32 ± 0.12 5.37 ± 0.14 
HDL cholesterol (mmol/l) 1.34 ± 0.06 1.33 ± 0.05 
Triglycerides (mmol/l) 1.49 ± 0.11 1.47 ± 0.14 
Adipokines 
 
Leptin (ng/ml) 
Adiponectin (µg/ml) 
62.4 ± 3.80 
7.01 ± 0.42 
61.2 ± 4.13 
6.81 ± 0.51 
Risk factors 
HDL <1.03 mmol/l (M), <1.29 mmol/l (F) 
 
25 (45) 
 
18 (46) 
Hypertension ≥ 130/85 mmHg 24 (44) 16 (41) 
Glucose ≥ 5.6 mmol/l 25 (45) 21 (54) 
Triglycerides ≥ 1.7 mmol/l 17 (31) 11 (28) 
Inflammatory factors   
TNF-α (pg/ml) 1.79 ± 0.07 1.87 ± 0.09 
Interleukin 6 (pg/ml) 2.63 ± 0.18 2.74 ± 0.23 
High-sensitivity CRP (mg/dl) 0.89 ± 0.09 0.91 ± 0.12 
Orosomucoid (g/l) 0.99 ± 0.03 0.99 ± 0.03 
Serum amyloid A (µg/ml) 31.5 ± 7.6 35.1 ± 10.1 
Hepatic factors   
AST (IU/l) 22.8 ± 1.57 23.7 ± 1.98 
Alanine aminotransferase (IU/l) 32.8 ± 3.76 33.5 ± 4.40 
ϒGT (mg/dl) 36.8 ± 2.95 37.1 ± 3.31 
Data are the means ± SE or n (%). Histology of hepatic biopsies was suitable for 39 individuals of the cohort, designated as the “liver subset.” 
No significant differences were observed between the two groups. 
 
(13). To our knowledge, no correlation between WAT 
macrophages and clinical or metabolic parameters of 
insulin resistance, type 2 diabetes, or other obesity-asso- 
ciated diseases has been reported in human studies. 
In humans, subcutaneous WAT is easier to obtain than 
visceral WAT for biopsies, and it is not known whether 
macrophage infiltration varies among WAT depots. A 
recent study indicates that visceral WAT contains increas- 
ing amounts of macrophages in obese individuals, similar 
to that observed in subcutaneous WAT (C. Curat, A. 
Bouloumié , personal communication). It is well known 
that visceral fat mass accumulation is linked to obesity 
comorbidities and is associated with increased risk of 
cardiovascular and hepatic diseases (14 –17). A wide range 
of liver lesions known as nonalcoholic fatty liver disease 
(NAFLD) has been shown to be associated with intra- 
abdominal fat mass in both men and women, independent 
of subcutaneous fat levels (18). NAFLD includes a large 
spectrum of lesions, from simple steatosis, considered to 
be benign, to inflammatory lesions called nonalcoholic 
steatohepatitis, which have the potential to progress to 
fibrosis, cirrhosis, and hepatocellular carcinoma. Omental 
WAT is drained by the portal venous system and has direct 
circulating connection with the liver. Thus, deregulated 
adipose production of fatty acids, adipokines, and/or in- 
flammatory factors by omental WAT in obesity might have 
an impact on liver function and morphology, as suggested 
by the “portal hypothesis” (19,20). However, there are no 
studies describing a potential relationship between infil- 
tration of macrophages in omental WAT and the compli- 
cations of obesity, in particular liver diseases. 
We tested the hypothesis that increased recruitment of 
macrophages in omental WAT is one of the cellular 
mechanisms linking increased visceral adiposity to obesi- 
ty-induced biological and histopathological liver abnor- 
malities. We evaluated the degree of macrophage 
infiltration in omental WAT compared with subcutaneous 
WAT in a cohort of 55 morbidly obese patients, and we 
examined potential relationships with clinical, metabolic, 
and hepatic anomalies. 
 
RESEARCH DESIGN AND METHODS 
A total of 55 morbidly obese subjects involved in a gastric surgery program 
were recruited at the Department of Nutrition of the Hô tel-Dieu Hospital 
(Paris, France). Clinical and biological parameters are shown in Table 1. 
Preoperative evaluation included medical history, physical, nutritional, car- 
diopulmonary, and psychological assessments. Obese subjects had been 
weight stable for at least 3 months before surgery. All patients met the criteria 
for obesity surgery, i.e., BMI ≥ 40 or ≥ 35 kg/m2 with at least two significant 
comorbidities (hypertension, type 2 diabetes, or dyslipidemia). They were 
excluded if they had evidence of acute or chronic inflammatory disease, 
infectious diseases, cancer, and/or known alcohol consumption (>20 g per 
day), as well as other causes of liver diseases (viral hepatitis, hemochroma- 
tosis, Wilson’s disease, autoimmune hepatitis, or œ-1 antitrypsine deficit). The 
ethics committees of the Hô tel-Dieu Hospital approved the clinical investiga- 
tions, and all subjects gave informed consent. Increased metabolic risk factors 
were present in 31– 45% of the whole population. The risk factors presented in 
Table 1 are surrogates of the metabolic syndrome components, as defined by 
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the AHA (American Heart Association) science advisory and coordinating 
committee and by the NHLBI (National Heart, Lung, and Blood Institute). 
According to the criteria of fasting glycemia >7 mmol/l or treatment, 12 of 55 
subjects were type 2 diabetic patients (Table 1). Among them, seven were 
treated with metformin and/or hypolipemic drugs. 
Immunomorphologic analysis of adipose tissue. Paired omental WAT and 
subcutaneous WAT biopsies were obtained during gastric surgery. A portion 
of each WAT biopsy was immediately transferred into liquid nitrogen before 
RNA analysis. The other part was fixed overnight at 4°C in 4% paraformalde- 
hyde and then processed for standard paraffin embedding. Sections of 5 µm 
were stained as described below and observed under a Zeiss 20 Axiostar Plus 
microscope (Zeiss, Gö ttingen, Germany). Digital images were captured by a 
camera (triCCD; Sony, Paris, France). Adipocyte diameters were measured, 
using PerfectImage software (Claravision, Orsay, France). Immunohistochem- 
ical detection of HAM56 (Dako Cytomation, Trappes, France) was performed 
with the avidin-biotin peroxidase method (21). Dewaxed sections were 
processed through the following incubation steps: 1) antigen unmasking by 
750 W microwave washing in a solution of 10 mmol/l citrate buffer, pH 6.0, 
three times; 2) 3% hydrogen peroxide in water for 15 min to block endogenous 
peroxidases; 3) Tris-buffered saline/Tween 20/casein 0.02 mol/l solution 
(TBS-TC) for 10 min; 4) monoclonal mouse antibodies diluted 1:100 (1 h) in 
TBS-TC at 4°C; and 5) multilink anti-mouse biotinylated immunoglobulins 
(Dako Cytomation) diluted 1:200 in TBS-TC for 20 min. Standard streptavidin- 
biotin-peroxidase complex method was applied using a commercially avail- 
able kit (AbCYS Biospa, Milan, Italy), and the staining was visualized using 
diaminobenzidine (Dako Cytomation). Slides were counterstained with May- 
er’s hematoxylin. Method specificity tests were performed by omission of 
primary antibodies and use of preimmune serum. Adipocytes and HAM56+ 
cells were counted in 10 different randomly chosen areas in each processed slide 
with 40X magnifi Counting was performed blindly by three independent 
observers. 
Liver histopathology. A liver biopsy was performed in each of the 55 
enrolled patients, and a subset of 39 biopsies of this cohort was suitable for 
histological evaluation. Liver samples were fixed in formalin, embedded in 
paraffin, and routinely stained (hematoxylin and eosin, Masson’s trichrome, 
picrosirius red, and Perls’ staining). Slides were coded and analyzed by a 
single expert pathologist blind to the identity of the biopsy. Major histopatho- 
logical features were recorded and semiquantitated according to previously 
published criteria (22). The amount of steatosis was scored as followed: 0 
(0 –5%), 1 (5–33%), 2 (34 – 66%), and 3 (>67%). Foci of lobular inflammation 
were defined as two or more inflammatory cells averaged from three to four 
fields counted at 20X magnification and then classified as 0 (no foci), 1 (<2), 
2 (2– 4), and 3 (>4). Portal inflammation was evaluated by inflammatory 
infiltrate, mainly mononuclear cells, assessed from low magnification and 
scored 0 (none to minimal) or 1 (greater than minimal). Fibrosis was classed 
as stage 0 (none), stage 1 (1a-b zone 3 perisinusoidal fibrosis only, 1c portal 
fibrosis only), stage 2 (zone 3 perisinusoidal fibrosis and periportal fibrosis 
without bridging), stage 3 (bridging fibrosis), and stage 4 (cirrhosis, probable 
and definite). Because the stage of fibrosis and the grade of inflammation are 
part of the spectrum that differentiates simple steatosis from steatohepatitis, 
we established an overall score of severity by adding elementary scores of 
fibrosis, portal inflammation, and lobular inflammation. Using this method, 
histopathological liver damage was either absent (score = 0), mild (1 or 2), or 
marked (>2). 
Laboratory tests. Blood samples were collected after an overnight fast of 
12 h. Plasma glucose, cholesterol, and HDL cholesterol levels were measured 
enzymatically. Serum insulin concentrations were determined with an immu- 
noradiometric assay kit (Bi-Insulin IRMA; CisBio International, Saclay, 
France). Serum amyloid A concentrations were measured, using an enzyme- 
linked immunosorbent assay Cytoscreen immunoassay kit (BioSource Inter- 
national, Camarilla, CA). Serum leptin and adiponectin were determined, 
using radioimmunoassay kits from Linco Research (St. Louis, MO), according 
to the manufacturer’s instructions. Interleukin 6 and tumor necrosis factor 
(TNF)-œ serum levels were measured by an ultrasensitive enzyme-linked 
immunosorbent assay system (Quantikine; R&D System Europe, Abingdon, 
U.K.). Orosomucoid and high-sensitivity C-reactive protein were measured 
using an Immage automatic immunoassay system (Beckman-Coulter, Fuller- 
ton, CA). Insulin sensitivity was evaluated by the quantitative insulin sensi- 
tivity check index (QUICKI) method. Calculation was performed from fasting 
glucose and insulin as previously described (23). 
Statistical analyses. Data are the means ± SE. The Shapiro-Wilcoxon test 
was used to test the Gaussian distribution of all clinical and biological 
parameters. Skewed variables were log-transformed to normalize their distri- 
bution before statistical analyses. We verified the normality of log-trans- 
formed variables. Relationships between WAT macrophage infiltration and 
quantitative clinical and biological variables were explored by logistic regres- 
sion. ANOVA was used for quantitative traits and x2 test for noncontinuous 
 
 
 
FIG. 1. Immunohistochemical detection of HAM 56+ macrophages in 
omental WAT (A and C) and subcutaneous WAT (B and D) of one 
representative obese woman. A: Macrophages are both dispersed into 
the omental WAT parenchyma and in crown arrangement (A, arrow 
heads). B: Only crown-like structures are visible in subcutaneous WAT 
parenchyma. Higher magnification (60x) of crown structures in omen- 
tal WAT (C) and subcutaneous WAT (D). oWAT, omental WAT; scWAT, 
subcutaneous  WAT. 
 
values. We used a stepwise variable method of selection to predict the degree 
of WAT macrophage infiltration and the score of liver lesions. Statistical 
analysis was performed with JMP statistics software (SAS Institute, Cary, NC). 
P < 0.05 was considered significant. 
 
RESULTS 
Macrophages were identified on immunoreactivity for the 
HAM56 marker in paired subcutaneous WAT and omental 
WAT biopsies sampled from the same obese individual. 
Numerous single HAM56+ cells were dispersed through- 
out the parenchyma in omental WAT (Fig. 1A), whereas 
these isolated immune cells were virtually absent in sub- 
cutaneous WAT (Fig. 1B). A “crown” organization of 
macrophages around a single adipocyte was observed in 
omental WAT (Fig. 1A and B), with two adjacent crowns 
with numerous macrophages sometimes visible (Fig. 1C). 
By contrast, in the crowns present in subcutaneous WAT, 
there were markedly fewer macrophages (Fig. 1D). 
To quantify the abundance of macrophage infiltrates, 
HAM56+ cells were systematically counted on each pro- 
cessed slide. The number of macrophages was normalized 
to 100 adipocytes for comparison between tissues and 
between patients. The number of infiltrated macrophages 
was twice as high in omental WAT as in subcutaneous 
WAT (30.1 ± 2.4 vs. 14.8 ± 1.8%, respectively; P < 0.0001) 
(Fig. 2A). Higher expression (by RT– quantitative PCR) of 
two macrophage markers (CD11b and CD87) in omental 
than in subcutaneous WAT confirmed direct cell quantifi- 
cation (data not shown). 
Because adipocyte hypertrophy is a factor determining 
WAT macrophage infiltration (3,6), we assessed the rela- 
tionship between adipose cell diameter and the percentage 
of macrophages in omental and subcutaneous WAT. The 
mean diameter of omental adipose cells was significantly 
smaller than that of subcutaneous cells (73.1 ± 1.8 vs. 
86.3 ± 1.7 µm, P < 0.0001) (Fig. 2B). Thus, there was 
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FIG. 2. Percentage of macrophage infiltration (A) and adipocyte diam- 
eter (B) in omental WAT (f) and subcutaneous WAT (0). Data are the 
means ± SE. *P < 0.01; **P < 0.001. C: Correlations between the 
percentage of macrophage infiltration and adipocyte diameter in omen- 
tal WAT (f) and subcutaneous WAT (0). Lines are linear regressions 
in omental WAT (solid line) and in subcutaneous WAT (dotted line). 
oWAT, omental WAT; scWAT, subcutaneous WAT. 
 
 
greater macrophage infiltration in omental than in subcu- 
taneous WAT, despite the smaller adipose cell size. Within 
each fat depot, there was a positive correlation between 
adipose cell diameter and the number of infiltrating mac- 
rophages (R2 = 0.19, P = 0.001, in omental WAT, and R2 = 
0.13, P = 0.010, in subcutaneous WAT) (Fig. 2C). Thus, fat 
cell hypertrophy is not the sole determinant of macro- 
phage recruitment into WAT; it is also dependent on the 
localization of anatomic fat depot. Systemic metabolic or 
hormonal factors cannot explain this site-associated dif- 
ference because both types of WAT were obtained from 
the same subject. There was no significant correlation 
between the degree of macrophage infiltration in omental 
WAT and that in subcutaneous WAT in the same individual 
(R2 = 0.08, P = 0.58). 
Linear regression was performed to examine the rela- 
tionships between the percentage of macrophage infiltra- 
tion  in  omental  WAT  and  clinical  and  biological 
 
 
 
FIG. 3. Correlations between the percentage of macrophages and 
triglycerides (A) or HDL cholesterol (B) in omental WAT (f) and 
subcutaneous WAT (0). Lines are linear regressions in omental WAT 
(solid line) and in subcutaneous WAT (dotted line). 
 
 
parameters. The percentage of macrophages in omental 
WAT was significantly related to age at surgery (R2 = 0.07, 
P = 0.045) in the whole population of 55 subjects. Thus, 
subsequent linear regressions were adjusted for age. In 
contrast, only a trend toward a correlation (P = 0.06) was 
found with the subject’s BMI. We found that omental WAT 
macrophage infiltration was positively related to fasting 
concentrations of glucose (R2 = 0.17, P = 0.02) and insulin 
(R2 = 0.17, P = 0.02) and negatively associated with a 
marker of insulin sensitivity, QUICKI (R2 = 0.15, P = 0.04). 
Strong positive and negative relationships were found with 
triglycerides (R2 = 0.25, P = 0.0009) (Fig. 3A) and with 
HDL cholesterol (R2 = 0.21, P = 0.005), respectively (Fig. 
3B). The hepatic parameters aspartate aminotransferase 
(AST; R2 = 0.19, P = 0.009) and ϒ-glutamyltranspeptidase 
(ϒGT; R2 = 0.15, P = 0.04) were also associated with the 
percentage of macrophages in omental WAT. Strikingly, 
none of these relationships was found with the amount of 
macrophage infiltration in subcutaneous WAT (Fig. 3). We 
found no association between omental WAT macrophage 
infiltration and systemic inflammatory parameters (oroso- 
mucoid, serum amyloid A, or high-sensitivity C-reactive 
protein) and a trend toward an association for interleukin 
6 (R2 = 0.13, P = 0.09) and TNF-œ (R2 = 0.14, P = 0.07). 
ANOVA revealed that the degree of macrophage infiltra- 
tion in omental WAT was also strongly associated with sex 
(P = 0.004) as well as with triglycerides >1.7 mmol/l (P = 
0.01) and more moderately with HDL cholesterol–linked 
metabolic risk (P = 0.09). After adjustment of all signifi- 
cant quantitative variables for age and sex, only fasting 
triglyceride concentrations (P = 0.026) and the triglyceri- 
de–to–HDL cholesterol ratio (P = 0.012) remained associ- 
ated with the percentage of macrophages in omental WAT, 
indicating a substantial sex and age effect on other vari- 
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TABLE 2 
Clinical and biological parameters of 39 obese patients classified by the severity of liver fibroinflammatory scores 
 
  Hepatic fibroinflammatory score  
Absent (0) Mild (1–2) Marked (>2) P 
n 7 17 15 — 
F/M 6/1 (86) 16/1 (94) 9/6 (60) — 
Age (years) 41.4 ± 4.6 37.4 ± 2.5 39.0 ± 2.5 0.67 
BMI (kg/m2) 44.5 ± 3.5 47.6 ± 1.5 49.8 ± 1.9 0.28 
Glucose (mmol/l) 5.57 ± 0.39 5.79 ± 0.37 7.17 ± 0.71* 0.11 
Insulin (µU/ml) 8.9 ± 1.75 14.5 ± 1.76 19.3 ± 2.82† 0.036 
QUICKI 0.35 0.32‡ 0.30* 0.009 
Type 2 diabetes 0 3 (18) 6 (40) 0.09 
Cholesterol  (mmol/l) 5.63 ± 0.24 5.23 ± 0.18 5.47 ± 0.29 0.56 
HDL cholesterol (mmol/l) 1.53 ± 0.15 1.35 ± 0.09 1.24 ± 0.06 0.26 
Triglycerides (mmol/l) 1.17 ± 0.10 1.26 ± 0.17 1.89 ± 0.29* 0.11 
Triglyceride–to–HDL cholesterol ratio 0.84 ± 0.40 1.04 ± 0.25 1.74 ± 0.27 0.10 
Leptin (ng/ml) 49.8 ± 5.52 69.4 ± 6.00 56.7 ± 7.9 0.14 
Adiponectin (µg/ml) 7.19 ± 1.35 7.82 ± 0.90 5.59 ± 0.59* 0.11 
TNF-α (pg/ml) 1.87 ± 0.16 1.85 ± 0.18 1.90 ± 0.11 0.84 
Interleukin 6 (pg/ml) 2.34 ± 0.61 2.54 ± 0.28 3.12 ± 0.41 0.33 
High-sensitivity CRP (mg/dl) 1.09 ± 0.41 0.79 ± 0.13 0.97 ± 0.22 0.82 
Orosomucoid (g/l) 1.00 ± 0.07 1.04 ± 0.05 0.93 ± 0.04 0.37 
Serum amyloid A (µg/ml) 21.8 ± 8.6 36.8 ± 15.5 39.4 ± 19.7 0.83 
HDL <1.03 mmol/l (M), <1.29 mmol/l (F) 2 (29) 8 (44) 8 (53) 0.55 
Hypertension ≥130/85 mmHg 2 (29) 6 (35) 8 (53) 0.44 
Glucose ≥ 5.6 mmol/l 3 (43) 8 (44) 10 (66) 0.43 
Triglycerides ≥ 1.7 mmol/l 0 3 (18)‡ 8 (53)* 0.015 
Macrophages in omental WAT (%) 22.2 ± 7.2 24.9 ± 3.8‡ 40.7 ± 4.5* 0.016 
Adipocyte diameter omental WAT (µm) 72.8 ± 7.6 72.3 ± 4.2 75.2 ± 3.1 0.75 
Macrophages in subcutaneous WAT (%) 15.5 ± 1.53 14.9 ± 2.47 12.2 ± 3.13 0.12 
Adipocyte diameter in subcutaneous WAT (µm) 95.8 ± 5.05 84.0 ± 3.6 85.2 ± 2.8 0.11 
AST (IU/l) 19.7 ± 3.3 19.6 ± 1.2 30.4 ± 4.3* 0.012 
Alanine aminotransferase (IU/l) 27.7 ± 10.9 25.9 ± 2.8 45.3 ± 9.3† 0.043 
ϒGT (mg/dl) 32.3 ± 10.9 32.6 ± 3.9 45.4 ± 5.3† 0.045 
Data are the means ± SE, R2, or n (%). P values were obtained by ANOVA test for continuous values or by x2 test for noncontinuous values. 
A different label (*, †, ‡) indicates significant differences using Student’s t test for each pair (P < 0.05 for *mild vs. marked, †absent vs. 
marked, and ‡absent vs. mild, respectively). 
 
ables. In addition, the association between triglycerides 
and omental WAT macrophages remained statistically 
significant after adjustment for diabetes status (P = 0.03) 
or exclusion of patients undergoing hypolipemic treatment 
(P = 0.04). 
We used a forward-variable method of selection to 
identify the best model to estimate the degree of macro- 
phage infiltration. Variables were added according to a 
criterion based on the decrease of the error sum of squares 
(criterion based on F value of the ANOVA). This model 
showed that macrophage infiltration in omental WAT was 
best predicted by fasting triglyceride values, sex, and age. 
These parameters can be used to derive an equation that 
estimates the percentage of macrophage infiltration in 
omental WAT as follows: 12.163 + 9.98 (X 1 if sex = M, 
or X 0 if sex = F) + 0.332 X age + 11.491 X (log fasting 
triglyceride in mmol/l). This model explains 30% of the 
variability of macrophage infiltration in omental WAT. 
To test the hypothesis that increased macrophage infil- 
tration in omental WAT could be involved in the severity of 
liver lesions, we performed a detailed semiquantitative 
histological analysis of liver biopsies in 39 subjects. Clin- 
ical and biological parameters were not significantly dif- 
ferent between this group and the entire studied 
population (Table 1). We used a score of histological 
severity that takes into consideration both inflammatory 
parameters (lobular and portal inflammation) and fibrosis. 
This score identified three groups of patients according to 
 
the severity of hepatic lesions (absent, mild, and marked) 
(Table 2). In our population of 39 obese subjects, 17.9% 
had no histological severity and 43.5% presented mild 
inflammatory lesions (score 1 to 2), whereas 38.5% had 
marked lesions (score >2). Patients with marked lesions 
had a more severe biological phenotype. They had signif- 
icantly increased insulinemia, reduced QUICKI, and higher 
hepatic factors (AST, alanine aminotransferase, and )IGT) 
compared with the mild and/or absent groups (Table 2). 
The proportion of type 2 diabetic patients in this group 
was higher, although not significantly (P = 0.09), than in 
the group with mild hepatic lesions (Table 2). There were 
trends toward association between the severity of hepatic 
lesions and increased fasting glucose, increased fasting 
triglycerides, and decreased adiponectin plasma concen- 
trations, which can be explained by significant differences 
between patients with mild and marked lesions. 
In agreement with our initial hypothesis, omental WAT 
macrophage accumulation was significantly associated 
with severity of fibroinflammatory liver damage (P = 
0.016) (Table 2). This effect was also observed when the 
subgroup (n = 31) of women was analyzed separately 
(P = 0.030) (data not shown). The percentage of macro- 
phage infiltration in omental WAT was almost double in 
the group with marked fibroinflammatory lesions com- 
pared with the group without or with mild alterations 
(Table 2 and Fig. 4A). By contrast, the score of steatosis 
alone was not significantly related to macrophage infiltra- 
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FIG. 4. Percentage of macrophages in omental WAT (A) and in subcu- 
taneous WAT (B) in 39 subjects scored for hepatic fibroinflammatory 
lesions. Horizontal lines are the mean value in each group. *P < 0.05 
using Student’s test for each pair, compared with mild and absent 
group. oWAT, omental WAT; scWAT, subcutaneous WAT. 
 
 
tion in omental WAT (data not shown). No correlation was 
found between subcutaneous WAT macrophage infiltra- 
tion and the severity of hepatic lesions (P = 0.12) (Table 2 
and Fig. 4B). Using a stepwise selection algorithm based 
on Akaike information criteria, we fit the best logistic 
regression, using significant variables to predict the sever- 
ity of hepatic lesions (marked group). The best predictive 
model included the three variables: adiponectinemia, AST 
levels, and percentage of macrophage in omental WAT 
(total deviance 50 with 36 degrees of freedom [df], residual 
deviance 35 with 33 df, Akaike information criteria = 
42.923). The predicting odds ratio for being in the severe 
class of hepatic fibroinflammatory lesions can be com- 
puted as: e(-5.217 + 2.103 X log AST + 0.060 X % 
macrophages in omental WAT - 1.797 X log adiponectin). 
Interestingly, the replacement of measured omental WAT 
macrophages by values calculated with the equation de- 
fined above using age, sex, and triglycerides did not 
significantly alter this predictive equation. 
 
DISCUSSION 
The presence of resident macrophages in WAT and their 
increased recruitment during obesity was recently estab- 
lished in both humans and rodents (3– 6). At present, the 
pathological consequences of macrophage infiltration in 
WAT remain hypothetical. One key unanswered question 
is whether increased macrophage infiltration in a particu- 
lar WAT depot is associated with specific obesity comor- 
bidities. This study clearly shows that macrophage 
accumulation in WAT is dependent on anatomical local- 
ization. Indeed, there is twice as much infiltration in 
omental as in subcutaneous WAT. In addition, omental 
WAT macrophage accumulation is significantly associated 
with severe hepatic fibroinflammatory lesions in morbid 
obesity in humans. 
To our knowledge, this is the first study to demonstrate 
a difference between macrophage accumulation in omen- 
tal and subcutaneous WAT, based on direct quantification 
of infiltrating HAM56+ cells on adipose tissue slides. 
CD68+ cells have been shown to be more common in 
visceral than in subcutaneous WAT in normal-weight 
human subjects (10), suggesting that increased omental 
WAT infiltration includes nonobese individuals. The de- 
gree of macrophage infiltration represents a new WAT 
site–related difference, in addition to distinct metabolic 
capacities, gene expression, secretory functions, and hor- 
monal responsiveness (24). The actual factors responsible 
for the higher recruitment of macrophages in omental than 
in subcutaneous WAT are unknown. In animal models of 
obesity, a relationship has been shown between adipose 
cell size and the amount of macrophages in the stroma 
vascular fraction of WAT (3). The current study indicates 
that in addition to adipose cell hypertrophy, depot-specific 
vascularization and/or innervation might explain distinct 
WAT infiltration with immune cells. 
Our most important finding is that omental WAT mac- 
rophage accumulation is significantly associated with se- 
vere hepatic fibroinflammatory lesions, which were found 
in  ̴40% of the morbidly obese population. This deleteri- 
ous association appears to be specific for macrophage 
infiltration in omental WAT because no relationship was 
observed between histological liver damage  and the 
amount of macrophages in subcutaneous WAT. The robust 
correlation found in the entire population between omen- 
tal WAT macrophages and two hepatic parameters, AST 
and ϒGT, supports the hypothesis that omental WAT 
macrophage infiltration contributes to worsen liver dam- 
age. This is the first report identifying an association 
between macrophage infiltration in WAT and a comorbid- 
ity in human obesity. 
The molecular mechanisms linking macrophage infiltra- 
tion in omental WAT and hepatic alterations are yet to be 
investigated. Recent studies in humans have evaluated the 
implication of adipokines, such as leptin, adiponectin, and 
TNF-α, in the pathogenesis of liver diseases (25–27). In our 
population of massively obese patients, neither leptin nor 
TNF-α circulating levels were significantly associated with 
the severity of hepatic lesions. Regarding adiponectin, 
previous studies (26,27) have shown that low circulating 
levels associate with worsening grades of hepatic necro- 
inflammation. In the current study, the obese patients with 
marked hepatic fibroinflammatory lesions displayed signif- 
icantly reduced adiponectin levels. These observations 
suggest a role for adiponectin to protect from liver inflam- 
matory damage. Whether macrophage infiltration in omen- 
tal WAT contributes to reduce adiponectin production in 
human obesity is currently unknown. 
In our correlation study, triglycerides were the best 
predictor of omental WAT macrophage infiltration and 
increased with the severity of hepatic lesions. Because 
triglycerides are also increased in type 2 diabetes, we 
examined various parameters in diabetic versus nondia- 
betic subjects in our population. Our data suggest that 
diabetes is not a major determinant of omental WAT 
macrophage accumulation. Regarding the severity of he- 
patic lesions, there is a trend toward an increased number 
of diabetic subjects in the “marked” groups versus the 
“mild” group. It should be noted, however, that the small 
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number of diabetic subjects in our cohort might account 
for the absence of statistical differences. Further studies 
including obese and nonobese diabetic subjects are 
needed to assess whether diabetes contributes to aggra- 
vate liver lesions in humans. 
NAFLD includes a wide spectrum of diseases, from pure 
steatosis to nonalcoholic steatohepatitis in the absence of 
significant alcohol consumption. Although steatosis is 
considered a nonprogressive disease, nonalcoholic steato- 
hepatitis may deteriorate in advanced chronic liver dis- 
eases, cirrhosis, and hepatocellular carcinoma (28). 
Worsening of steatosis is associated with the progression 
of fibrosis in patients with chronic hepatitis (29,30). The 
histopathological criteria that differentiate steatosis from 
nonalcoholic steatohepatitis have not been uniformly de- 
fined. Fibrosis is an obvious marker of severity, and a 
score has recently been proposed (22). In addition, portal 
or lobular inflammation tends to result in the development 
of fibrosis. Therefore, in the current study, we scored the 
severity of liver histopathology with a semiquantitative 
evaluation of inflammation and fibrosis, two patterns of 
which are part of nonalcoholic steatohepatitis in most 
published reports. This classification identified a group of 
patients with severe fibroinflammation and a high degree 
of macrophage infiltration in omental WAT. Current un- 
derstanding of the causes, mechanisms, and implications 
of obesity-associated liver damage is poor. Recent stable 
isotope studies in obese NAFLD patients demonstrated 
that nearly 60% of the triacylglycerol found in the liver 
arose from the nonesterified fatty acid pool in the serum, 
60 – 80% of which comes from adipose tissue lipolysis (31). 
Activated macrophages secrete numerous cytokines that 
activate lipolysis through various signaling pathways con- 
verging on phosphorylation of hormone-sensitive lipase or 
its associated proteins, such as perilipins (32). In obese 
individuals, the presence of infiltrating macrophages in 
omental WAT might increase nonesterified fatty acid de- 
livery to the liver and aggravate steatosis, paving the way 
for more severe hepatic damage. As macrophage infiltra- 
tion increases in omental WAT, inflammatory molecules 
could reach the liver directly through the portal system 
and act in concert with locally produced proinflammatory 
factors (33) to increase liver cell apoptosis, a prerequisite 
for developing fibrosis. To what extent this deleterious 
process is triggered by factors released from omental WAT 
macrophages or from resident macrophages in liver (Kü p- 
pfer cells) remains to be determined. Although measure- 
ment of inflammatory molecules in the portal system 
would be informative, this is not feasible in humans. 
A recent longitudinal study in NAFLD patients, using 
sequential liver biopsy, showed that fibrosis progresses in 
37% of patients, with a high variability in the rate of 
progression among subjects (34). This emphasizes the 
need for predictive parameters to evaluate the amount of 
hepatic damage. A clinical-biological score combining 
BMI, age, alanine aminotransferase, and triglycerides has 
been proposed to predict septal fibrosis in overweight 
patients (35). In this study, we used a stepwise approach 
to find the best clinical and biological predictors of severe 
hepatic fibroinflammatory lesions from data, including the 
measurement of candidate inflammatory biomolecules and 
the amount of macrophages in omental WAT. A model 
combining adiponectin, AST, and omental WAT macro- 
phages (directly measured or estimated from age, sex, and 
triglycerides) was shown to be the best combination 
associated with the degree of fibroinflammatory hepatic 
lesions. This finding supports a deleterious role for mac- 
rophage infiltration in omental WAT and reduced circulat- 
ing adiponectin levels in the worsening of hepatic 
fibroinflammatory lesions. 
In conclusion, this is the first demonstration of a link 
between omental WAT macrophage accumulation and 
severe hepatic inflammatory damages in human obesity. 
The predictive equation that we propose could be used as 
a surrogate for liver biopsy in morbidly obese individuals 
to estimate the severity of hepatic damage. Currently, the 
validity of this model has to be considered only for 
morbidly obese patients. Future investigations of indepen- 
dent human cohorts with different degrees of liver disease 
and BMI should validate its accuracy and potential general 
application. In addition, because we found significant links 
among macrophage recruitment, triglycerides, and HDL 
cholesterol, the consequences of omental WAT macro- 
phage infiltration on cardiovascular disease related to 
obesity could be of interest in future studies. 
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Babany and Dale Roche) for editing the manuscript. 
 
REFERENCES 
1. Gordon S: The macrophage. Bioessays 17:977–986, 1995 
2. Loftus TM, Kuhajda FP, Lane MD: Insulin depletion leads to adipose- 
specific cell death in obese but not lean mice. Proc Natl Acad Sci U S A 
95:14168 –14172, 1998 
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 
Jr: Obesity is associated with macrophage accumulation in adipose tissue. 
J Clin Invest 112:1796 –1808, 2003 
4. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross 
JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role 
in the development of obesity-related insulin resistance. J Clin Invest 
112:1821–1830, 2003 
5. Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie 
A: From blood monocytes to adipose tissue-resident macrophages: induc- 
tion of diapedesis by human mature adipocytes. Diabetes 53:1285–1292, 
2004 
6. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye 
M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, 
Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K: 
Reduction of macrophage infiltration and chemoattractant gene expres- 
sion changes in white adipose tissue of morbidly obese subjects after 
surgery-induced weight loss. Diabetes 54:2277–2286, 2005 
7. Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, 
Laharrague P, Casteilla L, Penicaud L: A role for preadipocytes as 
macrophage-like cells. FASEB J 13:305–312, 1999 
8. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla 
L: Preadipocyte conversion to macrophage: evidence of plasticity. J Biol 
Chem 278:9850 –9855, 2003 
9. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N, 
Wendling O, Mark M, Desvergne B, Wahli W, Chambon P, Metzger D: 
Peroxisome proliferator-activated receptor gamma is required in mature 
white and brown adipocytes for their survival in the mouse. Proc Natl Acad 
Sci U S A 101:4543– 4547, 2004 
10. Bornstein SR, Abu-Asab M, Glasow A, Path G, Hauner H, Tsokos M, 
  
ADIPOSE MACROPHAGES AND HEPATIC INFLAMMATION 
 
 
 
Chrousos GP, Scherbaum WA: Immunohistochemical and ultrastructural 
localization of leptin and leptin receptor in human white adipose tissue 
and differentiating human adipose cells in primary culture. Diabetes 
49:532–538, 2000 
11. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, 
Fortier M, Greenberg AS, Obin MS: Adipocyte death defines macrophage 
localization and function in adipose tissue of obese mice and humans. J 
Lipid Res 46:2347–2355, 2005 
12. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, 
Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, 
Stich V, Cancello R, Langin D: Weight loss regulates inflammation-related 
genes in white adipose tissue of obese subjects. FASEB J 18:1657–1669, 
2004 
13. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo 
I, Leibel RL, Ferrante AW: CCR2 modulates inflammatory and metabolic 
effects of high-fat feeding. J Clin Invest 116:115–124, 2006 
14. Haslam DW, James WP: Obesity. Lancet 366:1197–1209, 2005 
15. Shankar SS, Steinberg HO: Obesity and endothelial dysfunction. Semin 
Vasc Med 5:56 – 64, 2005 
16. Qian Y, Fan JG: Obesity, fatty liver and liver cancer. Hepatobiliary 
Pancreat Dis Int 4:173–177, 2005 
17. Diehl AM: Hepatic complications of obesity. Gastroenterol Clin North Am 
34:45– 61, 2005 
18. Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, 
Hakkinen AM, Fredriksson J, Yki-Jarvinen H: Women and men have similar 
amounts of liver and intra-abdominal fat, despite more subcutaneous fat in 
women: implications for sex differences in markers of cardiovascular risk. 
Diabetologia 47:1360 –1369, 2004 
19. Frayn KN: Lipoproteins in health and disease. Eur J Clin Nutr 54: 273, 
2000 
20. Frayn KN: Visceral fat and insulin resistance: causative or correlative? Br J 
Nutr 83 (Suppl. 1):71–77, 2000 
21. Hsu SM, Raine L: Protein A, avidin, and biotin in immunohistochemistry. 
J Histochem Cytochem 29:1349 –1353, 1981 
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, 
Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, 
Sanyal AJ: Design and validation of a histological scoring system for 
nonalcoholic fatty liver disease. Hepatology 41:1313–1321, 2005 
23. Katz LE, DeLeon DD, Zhao H, Jawad AF: Free and total insulin-like growth 
factor (IGF)-I levels decline during fasting: relationships with insulin and 
IGF-binding protein-1. J Clin Endocrinol Metab 87:2978 –2983, 2002 
24. Lafontan M, Berlan M: Do regional differences in adipocyte biology provide 
new pathophysiological insights? Trends Pharmacol Sci 24:276 –283, 2003 
25. Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F: Adipokines and liver 
fibrosis. Eur Rev Med Pharmacol Sci 9:279 –284, 2005 
26. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J: Beyond 
insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40:46 – 
54, 2004 
27. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, 
Cassader M, Durazzo M, Rizzetto M, Pagano G: Hypoadiponectinemia 
predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunc- 
tion in nondiabetic nonobese patients with nonalcoholic steatohepatitis. 
Am J Gastroenterol 100:2438 –2446, 2005 
28. Schaffler A, Scholmerich J, Buchler C: Mechanisms of disease: adipocyto- 
kines and visceral adipose tissue– emerging role in nonalcoholic fatty liver 
disease. Nat Clin Pract Gastroenterol Hepatol 2:273–280, 2005 
29. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky 
JM, Dhumeaux D: Worsening of steatosis is an independent factor of 
fibrosis progression in untreated patients with chronic hepatitis C and 
paired liver biopsies. Gut 52:288 –292, 2003 
30. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L: Impact of 
steatosis on progression of fibrosis in patients with mild hepatitis C. 
Hepatology 41:82– 87, 2005 
31. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: 
Sources of fatty acids stored in liver and secreted via lipoproteins in 
patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351, 
2005 
32. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold 
KR, Grunfeld C: Effects of infection and inflammation on lipid and 
lipoprotein metabolism: mechanisms and consequences to the host. J 
Lipid Res 45:1169 –1196, 2004 
33. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: 
Local and systemic insulin resistance resulting from hepatic activation of 
IKK-beta and NF-kappaB. Nat Med 11:183–190, 2005 
34. Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of 
nonalcoholic fatty liver disease: a longitudinal study of 103 patients with 
sequential liver biopsies. J Hepatol 42:132–138, 2005 
35. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil 
L, Turpin G, Opolon P, Poynard T: Liver fibrosis in overweight patients. 
Gastroenterology 118:1117–1123, 2000 
